ClinicalTrials.gg
CompletedNCT04020341Updated Jun 22, 2023Results posted

A Study to Evaluate Efficacy and Safety of Gepotidacin in the Treatment of Uncomplicated Urinary Tract Infection (UTI)

A Phase 3 interventional study of Gepotidacin and Placebo matching nitrofurantoin in Urinary Tract Infections, sponsored by GlaxoSmithKline. Completed at 104 sites in 12 countries. Open to female participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2023-06-22.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,531
Allocation
Randomized
Ages
12 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies in Urinary Tract Infections by GlaxoSmithKline — 4 open to participants now, 4 under way, none of them phase 3. Urinary Tract Infections · GlaxoSmithKline.

Enrollment
2nd of 13
1,531 · median 61
Started
2019
the only one that year
Phase 3
4 of 14
none open now
Registered
4th of 14
by date

Among the 14 studies in Urinary Tract Infections by GlaxoSmithKline, this one is the 2nd largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2019, is one of 4 in phase 3, and was the 4th registered.

Urinary Tract Infections

804 studies on the registry are indexed under Urinary Tract Infections; 133 are open to participants now.

Browse Urinary Tract Infections studies →

Open to participants now

4 of the 14 studies in Urinary Tract Infections by GlaxoSmithKline are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 84 Urinary Tract Infections studies recruiting now, 50 (60%) set no upper age limit and 23 (27%) stop at 75 or younger; 15 take children under 18; 17 take healthy volunteers.

This study: 12 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Urinary Tract Infections by GlaxoSmithKline, or all of them as a file.
02

Study summary

The study will be conducted to evaluate the therapeutic response (combined per participant microbiological and clinical response) of oral gepotidacin compared to oral nitrofurantoin for treatment of uncomplicated UTI (acute cystitis) in adolescent and adult female participants.

03

Conditions studied

  • Urinary Tract Infections

Keywords

  • Acute cystitis
  • Efficacy
  • Gepotidacin
  • Nitrofurantoin
  • Urinary Tract Infection
  • Simple cystitis
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants having >=12 years of age at the time of signing the /assent and have a body weight >=40 kilograms (kg).
  • Participants having 2 or more of the following clinical signs and symptoms of acute cystitis with onset \<96 hours prior to study entry: dysuria, frequency, urgency, or lower abdominal pain.
  • Participants having nitrite or pyuria (greater than [>]15 white blood cells [WBC]/high power field [HPF] or the presence of 3 plus [+]/large leukocyte esterase) from a pretreatment clean-catch midstream urine sample based on local laboratory procedures.
  • The participant is female.
  • Participant is capable of giving signed informed consent/assent.

Exclusion criteria

Exclusion Criteria:

  • Participant resides in a nursing home or dependent care type-facility.
  • Participant has a >=40.0 kilogram per square meter (kg/m\^2) or a body mass index >=35.0 kg/m\^2 and is experiencing obesity-related health conditions such as uncontrolled high blood pressure or uncontrolled diabetes.
  • Participant has a history of sensitivity to the study treatments, or components thereof, or a history of a drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates her participation.
  • Participant is or has altered immune defenses that may predispose the participant to a higher risk of treatment failure and/or complications.
  • Participant has any of the following:

    1. Poorly controlled asthma or ; acute severe pain; active peptic ulcer disease; Parkinson disease; myasthenia gravis; Or
    2. Known acute porphyria.
    3. Any surgical or medical condition (active or chronic) that may interfere with drug absorption, distribution, metabolism, or excretion of the study treatment.
  • Participant has a known glucose-6-phosphate dehydrogenase deficiency.
  • Participant has a serious underlying disease that could be imminently life-threatening, or the participant is unlikely to survive for the duration of the study period.
  • Participant has acute cystitis that is known or suspected to be due to fungal, parasitic, or viral pathogens; or known or suspected to be due to Pseudomonas aeruginosa or Enterobacterales (other than Escherichia coli) as the contributing pathogen.
  • Participant has symptoms known or suspected to be caused by another disease process, such as asymptomatic bacteriuria, overactive bladder, chronic incontinence, or chronic interstitial cystitis, that may interfere with the clinical efficacy assessments or preclude complete resolution of acute cystitis symptoms.
  • Participant has an anatomical or physiological anomaly that predisposes the participant to UTIs or may be a source of persistent bacterial colonization, including calculi, obstruction or stricture of the urinary tract, primary renal disease (for example [e.g.], polycystic renal disease), or neurogenic bladder, or the participant has a history of anatomical or functional abnormalities of the urinary tract (e.g., chronic vesico-ureteral reflux, detrusor insufficiency).
  • Participant has an indwelling catheter, nephrostomy, ureter stent, or other foreign material in the urinary tract.
  • Participant who, in the opinion of the investigator, has an otherwise complicated UTI, an active upper UTI (e.g., pyelonephritis, urosepsis), signs and symptom onset >=96 hours before study entry, or a temperature >=101.4 Degrees Fahrenheit (F) (>=38 Degrees Celsius [C]), flank pain, chills, or any other manifestations suggestive of upper UTI.
  • Participant has known anuria, oliguria, or significant impairment of renal function ( \<60 milliliter per minute [mL/min] or elevated serum creatinine as determined by the investigator).
  • Participant presents with vaginal discharge at Baseline (e.g., suspected sexually transmitted disease).
  • Participant has congenital long syndrome or known prolongation of the corrected QT (QTc) interval.
  • Participant has uncompensated heart failure.
  • Participant has severe left ventricular hypertrophy.
  • Participant has a family history of QT prolongation or sudden death.
  • Participant has a recent history of vasovagal syncope or episodes of symptomatic bradycardia or brady-arrhythmia within the last 12 months.
  • Participant is taking QT-prolonging drugs or drugs known to increase the risk of torsades de pointes (TdP) per the www.crediblemeds.org. "Known Risk of TdP" category at the time of her Baseline Visit, which cannot be safely discontinued from the Baseline Visit to the TOC Visit; or the participant is taking a strong cytochrome P450 enzyme 3A4 () inhibitor.
  • For any participant >=12 to \<18 years of age, the participant has an abnormal (ECG) reading.
  • Participant has a QTc >450 millisecond (msec) or a QTc >480 msec for participants with bundle-branch block.
  • Participant has a documented or recent history of uncorrected hypokalemia within the past 3 months.
  • Participant has a known (ALT) value >2 times (ULN).
  • Participant has a known value >1.5 times ULN (isolated bilirubin >1.5 times ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35 percent [%]).
  • Participant has a current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones), including symptomatic viral hepatitis or moderate-to-severe liver insufficiency ( class B or C).
  • Participant has a previous history of cholestatic jaundice or hepatic dysfunction associated with nitrofurantoin.
  • Participant has received treatment with other systemic antimicrobials or systemic antifungals within 1 week before study entry.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,531 participants (actual)

Study arms

  • Experimental
    Gepotidacin

    Participants will be administered oral doses of 1500 milligrams (mg) gepotidacin plus nitrofurantoin matching placebo twice daily (BID); approximately every 12 hours for 5 days

    Drug: Gepotidacin · Drug: Placebo matching nitrofurantoin

  • Active comparator
    Nitrofurantoin

    Participants will be administered oral doses of 100 mg nitrofurantoin plus gepotidacin matching placebo BID; approximately every 12 hours for 5 days.

    Drug: Nitrofurantoin · Drug: Placebo matching gepotidacin

Interventions

  • Gepotidacin will be available as tablets containing 750 mg gepotidacin. Each dose should be taken with water after consumption of food.

  • DrugPlacebo matching nitrofurantoin

    Placebo matching nitrofurantoin will be available as over-encapsulated unit-dose capsules. Each dose should be taken with water after consumption of food.

  • Nitrofurantoin will be available as over-encapsulated capsules containing 25 mg nitrofurantoin macrocrystals and 75 mg nitrofurantoin. Each dose should be taken with water after consumption of food.

  • DrugPlacebo matching gepotidacin

    Placebo matching gepotidacin will be available as unit-dose gepotidacin placebo-to-match tablet. Each dose should be taken with water after consumption of food.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Therapeutic Response (TR) (Combined Per Participant Clinical and Microbiological Response) at the Test-of-Cure (TOC) Visit - Micro-ITT NTF-S (IA Set)

    Therapeutic response (success/failure) is a measure of the overall efficacy response. A therapeutic success referred to participants who had been deemed both a "microbiological success"(reduction of all qualifying bacterial uropathogens \[greater than or equal to {\>=}10\^5 colony-forming units per milliliter {CFU/mL}\] recovered at Baseline to less than (\<)10\^3 CFU/mL as observed on quantitative urine culture without the participant receiving other systemic antimicrobials before the TOC Visit) and a "clinical success" (resolution of signs and symptoms of acute cystitis present at Baseline \[and no new signs and symptoms\] without the participant receiving other systemic antimicrobials before the TOC Visit). Lack of clinical or microbiological success (including missing outcome assessments) was considered as therapeutic failure.

    Time frame: TOC visit (Days 9 to 16)

  2. Number of Participants With Therapeutic Response (TR) (Combined Per Participant Clinical and Microbiological Response) at the Test-of-Cure (TOC) Visit - Micro-ITT NTF-S Population

    TR at TOC (success/failure) is a measure of the overall efficacy response. A therapeutic success at TOC referred to participant who have been deemed both a microbiological success (reduction of all qualifying bacterial uropathogens recovered at Baseline \[BL\] to \<10\^3 colony forming units per milliliter \[CFU/mL\] without receiving other systemic antimicrobials \[AB\] before the TOC visit) and a clinical success (resolution of symptoms of acute cystitis present at BL and no new symptoms without receiving other AB before the TOC visit \[or AB for uUTI on day of TOC visit\]). Lack of clinical or microbiological success (including missing outcome assessments) was considered as therapeutic failure.

    Time frame: TOC visit (Days 9 to 16)

Secondary outcomes

  1. Number of Participants With Clinical Outcome at the TOC Visit - Micro-ITT NTF-S Population

    Clinical outcomes at TOC were categorized as clinical resolution, clinical improvement, clinical worsening and unable to determine. Clinical resolution at TOC was defined as resolution of signs and symptoms of acute cystitis present at baseline (BL) (and no symptoms) without receiving any other AB before the TOC visit. Clinical improvement at TOC was defined as improvement (but not complete resolution) in total symptom score (CSS) from BL, without receiving any other AB before the TOC visit. Clinical worsening at TOC was defined as worsening or no change in CSS from BL or received other AB for the current infection (uUTI) before or on the date of the TOC visit. Unable to determine outcome criteria were: BL score is missing (and thus improvement/worsening cannot be determined), TOC assessment is missing, or receipt of other AB not for the current infection before the TOC visit (unless clinical worsening outcome criteria were met).

    Time frame: TOC visit (Days 9 to 16)

  2. Number of Participants With Clinical Response at the TOC Visit - Micro-ITT NTF-S Population

    Clinical response at TOC was categorized as clinical success and clinical failure. Clinical success at TOC was defined as resolution of symptoms of acute cystitis present at BL (and no new symptoms), without receiving any other AB before the TOC visit. Lack of resolution, including receipt of an AB for uUTI at the TOC visit, or a missing outcome assessment was defined as Clinical Failure at TOC.

    Time frame: TOC visit (Days 9 to 16)

  3. Number of Participants With Microbiological Outcome (MO) at the TOC Visit - Micro-ITT NTF-S Population

    Participant-level MOs at TOC were categorized as microbiological eradication (ME), microbiological persistence (MP), microbiological recurrence (MR) and unable to determine (UTD). ME at TOC was defined as all baseline qualifying uropathogens (QUP) have an outcome of eradication at TOC (i.e., \<10\^3 CFU/mL without the participant receiving other systemic antimicrobials before the TOC Visit). MP at TOC was defined as at least 1 QUP has an outcome of persistence (≥10\^3 CFU/mL) at TOC. MR at TOC was defined as at least 1 QUP had an outcome of recurrence and none have an outcome of persistence at TOC. UTD at TOC was defined as all QUP outcomes are UTD at TOC.

    Time frame: TOC Visit (Days 9 to 16)

  4. Number of Participants With Microbiological Response at the TOC Visit - Micro-ITT NTF-S Population

    Participant-level microbiological response at TOC was categorized as microbiological success and microbiological failure. Microbiological success at TOC was defined as all baseline qualifying uropathogens (QUP)s had a microbiological outcome of eradication at TOC visit. Microbiological failure was defined as lack of microbiological success, including those participants with UTD outcomes.

    Time frame: TOC visit (Days 9 to 16)

  5. Number of Participants With Therapeutic Response (TR) (Combined Per Participant Clinical and Microbiological Response) at the Follow up (FU) Visit-Micro-ITT NTF-S Population

    TR at FU was categorized as therapeutic success and therapeutic failure. A therapeutic success at FU referred to participants who have been deemed both a microbiological success (reduction of all QUPs recovered at BL to \<10\^3 CFU/mL, following microbiological eradication at the TOC visit, without receiving other AB before the FU visit) and a clinical success (resolution of signs and symptoms of acute cystitis demonstrated at the TOC visit persist at the FU visit and no new signs and symptoms, without receiving other AB before the FU visit \[or AB for uUTI on day of FU visit\]). Lack of clinical or microbiological success (including missing outcome assessments) was considered as therapeutic failure.

    Time frame: FU visit (Days 21 to 31)

  6. Number of Participants With Clinical Outcome at the Follow up (FU) Visit - Micro-ITT NTF-S Population

    Clinical outcomes at FU were categorized as SCR, DCR, CI, CW, CR and UTD. SCR at FU was resolution of symptoms of acute cystitis demonstrated at the TOC persist at the FU (and no symptoms), without receiving other AB before the FU. DCR at FU was resolution of symptoms of acute cystitis present at BL after clinical failure at TOC without receiving AB before FU. CI at FU was improvement in CSS from BL, but not complete resolution without receiving AB before FU. CW at FU was worsening or no change in CSS at FU compared to BL after clinical failure at TOC or receiving other AB for the current infection (uUTI) before or on the date of the FU. CR at FU was symptoms of acute cystitis reoccur at FU after clinical success at TOC. Unable to determine outcome criteria at FU were BL score missing, FU assessment missing or received other AB not for the current infection (uUTI) prior to the assessment (unless CS or CR outcome criteria were met).

    Time frame: FU visit (Days 21 to 31)

  7. Number of Participants With Clinical Response at the Follow up (FU) Visit - Micro-ITT NTF-S Population

    Clinical response at FU was categorized as clinical success and clinical failure. Clinical success at FU was defined as resolution of symptoms of acute cystitis demonstrated at TOC persist at the FU visit (and no new symptoms), without receiving other AB before the FU visit. Lack of sustained clinical resolution or a missing outcome assessment was defined as clinical failure.

    Time frame: FU visit (Days 21 to 31)

  8. Number of Participants With Microbiological Outcome (MO) at the Follow up (FU) Visit - Micro-ITT NTF-S Population

    Participant-level MOs at FU were categorized as sustained microbiological eradication (SME), microbiological recurrence (MR), microbiological persistence (MP), delayed microbiological eradication (DME) and unable to determine (UTD). SME at FU was defined as all baseline QUPs had an outcome of sustained eradication at FU (i.e., \<10\^3 CFU/mL without the participant receiving other systemic antimicrobials before the FU Visit). MR at FU was defined as at least one QUP had an outcome of recurrence (≥10\^3 CFU/mL) and none had an outcome of persistence at FU. MP at FU was defined as at least one QUP had an outcome of persistence at FU. DME at FU was defined as at least one QUP had an outcome of delayed eradication and none had an outcome of persistence or recurrence at FU. UTD at FU was defined as all QUP outcomes were unable to determine at FU.

    Time frame: FU visit (Days 21 to 31)

  9. Number of Participants With Microbiological Response at the Follow up (FU) Visit - Micro-ITT NTF-S Population

    Participant- level microbiological response at FU was categorized as microbiological success and microbiological failure. Microbiological success at FU was defined as all baseline QUPs had a microbiological outcome of sustained eradication at FU visit. Microbiological failure at FU was defined as not meeting criteria of microbiological success including those participants with UTD outcome.

    Time frame: FU visit (Days 21 to 31)

  10. Number of Participants With Clinical Outcome at the TOC Visit - Intent-to-Treat (ITT) Population

    Clinical outcomes at TOC were categorized as clinical resolution, clinical improvement, clinical worsening and unable to determine. Clinical resolution at TOC was defined as resolution symptoms of acute cystitis present at baseline (BL) (and no symptoms) without receiving any other AB before the TOC visit. Clinical improvement at TOC was defined as improvement (but not complete resolution) in CSS from BL, without receiving any other AB before the TOC visit. Clinical worsening at TOC was defined as worsening or no change in CSS from BL or received other AB for the current infection (uUTI) before or on the date of the TOC visit. Unable to determine outcome criteria were: BL score is missing (and thus improvement/worsening cannot be determined), TOC assessment is missing, or receipt of other AB not for the current infection before the TOC visit (unless clinical worsening outcome criteria were met).

    Time frame: TOC visit (Days 9 to 16)

  11. Number of Participants With Clinical Response at the TOC Visit - Intent-to-Treat (ITT) Population

    Clinical response at TOC was categorized as clinical success and clinical failure. Clinical success at TOC was defined as resolution of signs and symptoms of acute cystitis present at BL (and no new symptoms), without receiving any other AB before the TOC visit. Lack of resolution, including receipt of an AB for uUTI at the TOC visit, or a missing outcome assessment was defined as Clinical Failure.

    Time frame: TOC visit (Days 9 to 16)

  12. Number of Participants With Clinical Outcome at the Follow up (FU) Visit - Intent-to-Treat (ITT) Population

    Clinical outcomes at FU were categorized as Sustained Clinical Response (SCR), Delayed Clinical Response (DCR), CI, CW, Clinical Recurrence (CR) and UTD. SCR at FU was resolution of symptoms of acute cystitis demonstrated at TOC persist at the FU (and no symptoms), without receiving other AB before the FU. DCR at FU was resolution of symptoms of acute cystitis present at BL after clinical failure at TOC without receiving AB before FU. CI at FU was improvement in CSS from BL, but not complete resolution without receiving AB before FU. CW at FU was worsening or no change in CSS at FU compared to BL after clinical failure at TOC or receiving other AB for the current infection (uUTI) before or on the date of the FU. CR at FU was symptoms of acute cystitis reoccur at FU after clinical success at TOC. UTD outcome criteria at FU were BL score missing, FU assessment missing or received other AB not for current infection (uUTI) prior to assessment (unless CS or CR outcome criteria were met).

    Time frame: FU visit (Days 21 to 31)

  13. Number of Participants With Clinical Response at the Follow up (FU) Visit - Intent-to-Treat (ITT) Population

    Clinical response at FU was categorized as clinical success and clinical failure. Clinical success at FU was defined as resolution of symptoms of acute cystitis demonstrated at TOC persist at the FU visit (and no new symptoms), without receiving other AB before the FU visit. Lack of sustained clinical resolution or a missing outcome assessment was defined as clinical failure.

    Time frame: FU visit (Days 21 to 31)

  14. Plasma Concentration of Gepotidacin

    Blood samples were collected for plasma concentration of gepotidacin.

    Time frame: Baseline (Day 1) 0-2 hour (h) and >2h post-dose; On-therapy (Day 2), morning (am) pre-dose, 0-6h, 6-8h, 8-10h, 10-12h post-dose, 0-2h, >2h evening (pm) post-dose; On-therapy (Day 3 to 5), 0-6h, 6-8h, 8-10h, 10-12h post-dose

  15. Urine Concentration of Gepotidacin

    Urine samples were collected from participants.

    Time frame: Baseline (Day 1) 0-2 hour (h) and >2h post-dose; On-therapy (Day 2), morning (am) pre-dose, 0-6h, 6-8h, 8-10h, 10-12h post-dose, 0-2h, >2h evening (pm) post-dose; On-therapy (Day 3 to 5), 0-6h, 6-8h, 8-10h, 10-12h post-dose

  16. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment.

    Time frame: From the time of first dose (Day 1) through the final follow-up visit (Day 21-31)

  17. Number of Participants With Serious Adverse Events (SAEs)

    An SAE is defined as any untoward medical occurrence that, at any dose may result in death or is life-threatening or requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity or is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment or is associated with liver injury and impaired liver function.

    Time frame: From the time of first dose (Day 1) through the final follow-up visit (Day 21-31)

  18. Change From Baseline in Hematology Parameters - Neutrophil Count, Lymphocyte Count, Monocyte Count, Eosinophil Count, Basophil Count and Platelet Count at On Therapy and Test of Cure Visit

    Blood samples were collected for the analysis of hematology parameters: neutrophil count, lymphocyte count, monocyte count, eosinophil count, basophil count and platelet count. Baseline is defined as the latest pre-dose assessment with a non-missing value.

    Time frame: Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)

  19. Change From Baseline in Hematology Parameter-hemoglobin Level at On Therapy and Test of Cure Visit

    Blood samples were collected for the analysis of hemoglobin level. Baseline is defined as the latest pre-dose assessment with a non-missing value.

    Time frame: Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)

  20. Change From Baseline in Hematology Parameter- Hematocrit Level at On Therapy and Test of Cure Visit

    Blood samples were collected for the analysis of hematocrit level. Baseline is defined as the latest pre-dose assessment with a non-missing value.

    Time frame: Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)

  21. Change From Baseline in Hematology Parameter- Erythrocytes Count at On Therapy and Test of Cure Visit

    Blood samples were collected for the analysis of erythrocytes count. Baseline is defined as the latest pre-dose assessment with a non-missing value.

    Time frame: Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)

  22. Change From Baseline in Hematology Parameter - Mean Corpuscular Hemoglobin (MCH) at On Therapy and Test of Cure Visit

    Blood samples were collected for the analysis of MCH. Baseline is defined as the latest pre-dose assessment with a non-missing value.

    Time frame: Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)

  23. Change From Baseline in Hematology Parameter - Mean Corpuscular Volume (MCV) at On Therapy and Test of Cure Visit

    Blood samples were collected for the analysis of MCV. Baseline is defined as the latest pre-dose assessment with a non-missing value.

    Time frame: Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)

  24. Change From Baseline in Clinical Chemistry Parameters - Serum Urea Nitrogen, Glucose, Calcium, Chloride, Sodium, Magnesium, Phosphate, and Potassium Levels at On Therapy and Test of Cure Visit

    Blood samples were collected for the analysis of clinical chemistry parameters. Baseline is defined as the latest pre-dose assessment with a non-missing value

    Time frame: Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)

  25. Change From Baseline in Clinical Chemistry Parameters - Total Bilirubin, Direct Bilirubin and Creatinine Levels at On Therapy and Test of Cure Visit

    Blood samples were collected for the analysis of clinical chemistry parameters. Baseline is defined as the latest pre-dose assessment with a non-missing value.

    Time frame: Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)

  26. Change From Baseline in Clinical Chemistry Parameters - Albumin and Protein Levels at On Therapy and Test of Cure Visit

    Blood samples were collected for the analysis of clinical chemistry parameters. Baseline is defined as the latest pre-dose assessment with a non-missing value.

    Time frame: Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)

  27. Change From Baseline in Clinical Chemistry Parameters - Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) and Alkaline Phosphatase (ALP) Levels at On Therapy and Test of Cure Visit

    Blood samples were collected for the analysis of clinical chemistry parameters. Baseline is defined as the latest pre-dose assessment with a non-missing value.

    Time frame: Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)

  28. Number of Participants With Urinalysis Dipstick Results at Baseline, On Therapy and Test of Cure Visit

    Urine samples were collected for urinalysis: Urine Glucose (GLU), Urine Protein (PRO), Urine Occult Blood (BLO), Urine Ketones (KET), Urine Nitrite (NIT) and Urine Leukocyte Esterase (LEU). Baseline is defined as the latest pre-dose assessment with a non-missing value. The dipstick test gives results in a semi-quantitative manner, and results can be read as Negative, Trace, Small, Moderate, Large, Positive, 50 mg/dL, 150 mg/dL, \>=500 mg/dL, 30 mg/dL, 100 mg/dL, 200 mg/dL, 5 mg/dL, 20 mg/dL and 80 mg/dL indicating concentrations in the urine sample. In the row title (GLU, Baseline, Negative), GLU indicates parameter, Baseline is the visit and Negative indicates the concentration in the urine sample. Data is presented in similar manner for all other parameters.

    Time frame: Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)

  29. Absolute Mean Values of Urine Specific Gravity at Baseline, On Therapy and Test of Cure Visit

    Urine samples were collected from participants to assess urine specific gravity. Baseline is defined as the latest pre-dose assessment with a non-missing value.

    Time frame: Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)

  30. Absolute Mean Values of Urine Potential of Hydrogen (pH) at Baseline, On Therapy and Test of Cure Visit

    Urine samples were collected from participants to assess urine pH levels. Baseline is defined as the latest pre-dose assessment with a non-missing value.

    Time frame: Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)

  31. Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at On-Therapy and Test of Cure Visit

    SBP and DBP were measured in a semi-supine position after 5 minutes rest. Baseline is defined as the latest pre-dose assessment with a non-missing value.

    Time frame: Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)

  32. Change From Baseline in Pulse Rate at On Therapy and Test of Cure Visit

    Pulse rate was measured in a semi-supine position after 5 minutes rest. Baseline is defined as the latest pre-dose assessment with a non-missing value.

    Time frame: Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)

  33. Change From Baseline in Body Temperature at On Therapy and Test of Cure Visit

    Temperature was measured in a semi-supine position after 5 minutes rest. Baseline is defined as the latest pre-dose assessment with a non-missing value.

    Time frame: Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)

07

Results

Posted Jun 22, 2023

Participant flow

Participant flow — Overall Study
MilestoneGepotidacinNitrofurantoin
Started767764
Safety population766760
Microbiological itt (micro itt) population401365
Micro-itt ntf-s population336298
Micro-itt ntf-s (ia set) population320287
Completed734736
Not completed3328
Withdrew: Adverse event86
Withdrew: Lost to follow-up82
Withdrew: Withdrawal by subject1616
Withdrew: Participant not able to swallow the tablet10
Withdrew: Physician decision02
Withdrew: Protocol deviation02

Outcome measures

PrimaryNumber of Participants With Therapeutic Response (TR) (Combined Per Participant Clinical and Microbiological Response) at the Test-of-Cure (TOC) Visit - Micro-ITT NTF-S (IA Set)

Therapeutic response (success/failure) is a measure of the overall efficacy response. A therapeutic success referred to participants who had been deemed both a "microbiological success"(reduction of all qualifying bacterial uropathogens \[greater than or equal to {\>=}10\^5 colony-forming units per milliliter {CFU/mL}\] recovered at Baseline to less than (\<)10\^3 CFU/mL as observed on quantitative urine culture without the participant receiving other systemic antimicrobials before the TOC Visit) and a "clinical success" (resolution of signs and symptoms of acute cystitis present at Baseline \[and no new signs and symptoms\] without the participant receiving other systemic antimicrobials before the TOC Visit). Lack of clinical or microbiological success (including missing outcome assessments) was considered as therapeutic failure.

Time frame:
TOC visit (Days 9 to 16)
Reported as:
Count of participants · Participants
Number of Participants With Therapeutic Response (TR) (Combined Per Participant Clinical and Microbiological Response) at the Test-of-Cure (TOC) Visit - Micro-ITT NTF-S (IA Set)
ParticipantsGepotidacinNitrofurantoin
Therapeutic Success162135
Therapeutic Failure158152
Statistical analysis
  • Gepotidacin vs Nitrofurantoin · Adjusted difference in percent: 4.3 · 95% CI -3.6 to 12.1
  • Gepotidacin vs Nitrofurantoin · 1-sided p-value for Test of Superiority · p = 0.1445 · Adjusted difference of percent: 4.3 · 95% CI -3.6 to 12.1
PrimaryNumber of Participants With Therapeutic Response (TR) (Combined Per Participant Clinical and Microbiological Response) at the Test-of-Cure (TOC) Visit - Micro-ITT NTF-S Population

TR at TOC (success/failure) is a measure of the overall efficacy response. A therapeutic success at TOC referred to participant who have been deemed both a microbiological success (reduction of all qualifying bacterial uropathogens recovered at Baseline \[BL\] to \<10\^3 colony forming units per milliliter \[CFU/mL\] without receiving other systemic antimicrobials \[AB\] before the TOC visit) and a clinical success (resolution of symptoms of acute cystitis present at BL and no new symptoms without receiving other AB before the TOC visit \[or AB for uUTI on day of TOC visit\]). Lack of clinical or microbiological success (including missing outcome assessments) was considered as therapeutic failure.

Time frame:
TOC visit (Days 9 to 16)
Reported as:
Count of participants · Participants
Number of Participants With Therapeutic Response (TR) (Combined Per Participant Clinical and Microbiological Response) at the Test-of-Cure (TOC) Visit - Micro-ITT NTF-S Population
ParticipantsGepotidacinNitrofurantoin
Therapeutic Success174140
Therapeutic Failure162158
SecondaryNumber of Participants With Clinical Outcome at the TOC Visit - Micro-ITT NTF-S Population

Clinical outcomes at TOC were categorized as clinical resolution, clinical improvement, clinical worsening and unable to determine. Clinical resolution at TOC was defined as resolution of signs and symptoms of acute cystitis present at baseline (BL) (and no symptoms) without receiving any other AB before the TOC visit. Clinical improvement at TOC was defined as improvement (but not complete resolution) in total symptom score (CSS) from BL, without receiving any other AB before the TOC visit. Clinical worsening at TOC was defined as worsening or no change in CSS from BL or received other AB for the current infection (uUTI) before or on the date of the TOC visit. Unable to determine outcome criteria were: BL score is missing (and thus improvement/worsening cannot be determined), TOC assessment is missing, or receipt of other AB not for the current infection before the TOC visit (unless clinical worsening outcome criteria were met).

Time frame:
TOC visit (Days 9 to 16)
Reported as:
Count of participants · Participants
Number of Participants With Clinical Outcome at the TOC Visit - Micro-ITT NTF-S Population
ParticipantsGepotidacinNitrofurantoin
Clinical resolution224196
Clinical improvement (CI)8275
Clinical worsening (CW)916
Unable to determine2111
SecondaryNumber of Participants With Clinical Response at the TOC Visit - Micro-ITT NTF-S Population

Clinical response at TOC was categorized as clinical success and clinical failure. Clinical success at TOC was defined as resolution of symptoms of acute cystitis present at BL (and no new symptoms), without receiving any other AB before the TOC visit. Lack of resolution, including receipt of an AB for uUTI at the TOC visit, or a missing outcome assessment was defined as Clinical Failure at TOC.

Time frame:
TOC visit (Days 9 to 16)
Reported as:
Count of participants · Participants
Number of Participants With Clinical Response at the TOC Visit - Micro-ITT NTF-S Population
ParticipantsGepotidacinNitrofurantoin
Clinical success224196
Clinical failure112102
SecondaryNumber of Participants With Microbiological Outcome (MO) at the TOC Visit - Micro-ITT NTF-S Population

Participant-level MOs at TOC were categorized as microbiological eradication (ME), microbiological persistence (MP), microbiological recurrence (MR) and unable to determine (UTD). ME at TOC was defined as all baseline qualifying uropathogens (QUP) have an outcome of eradication at TOC (i.e., \<10\^3 CFU/mL without the participant receiving other systemic antimicrobials before the TOC Visit). MP at TOC was defined as at least 1 QUP has an outcome of persistence (≥10\^3 CFU/mL) at TOC. MR at TOC was defined as at least 1 QUP had an outcome of recurrence and none have an outcome of persistence at TOC. UTD at TOC was defined as all QUP outcomes are UTD at TOC.

Time frame:
TOC Visit (Days 9 to 16)
Reported as:
Count of participants · Participants
Number of Participants With Microbiological Outcome (MO) at the TOC Visit - Micro-ITT NTF-S Population
ParticipantsGepotidacinNitrofurantoin
Microbiological Eradication (ME)244199
Microbiological Persistence (MP)1521
Microbiological Recurrence (MR)3652
Unable to determine (UTD)4126
SecondaryNumber of Participants With Microbiological Response at the TOC Visit - Micro-ITT NTF-S Population

Participant-level microbiological response at TOC was categorized as microbiological success and microbiological failure. Microbiological success at TOC was defined as all baseline qualifying uropathogens (QUP)s had a microbiological outcome of eradication at TOC visit. Microbiological failure was defined as lack of microbiological success, including those participants with UTD outcomes.

Time frame:
TOC visit (Days 9 to 16)
Reported as:
Count of participants · Participants
Number of Participants With Microbiological Response at the TOC Visit - Micro-ITT NTF-S Population
ParticipantsGepotidacinNitrofurantoin
Microbiological success244199
Microbiological failure9299
SecondaryNumber of Participants With Therapeutic Response (TR) (Combined Per Participant Clinical and Microbiological Response) at the Follow up (FU) Visit-Micro-ITT NTF-S Population

TR at FU was categorized as therapeutic success and therapeutic failure. A therapeutic success at FU referred to participants who have been deemed both a microbiological success (reduction of all QUPs recovered at BL to \<10\^3 CFU/mL, following microbiological eradication at the TOC visit, without receiving other AB before the FU visit) and a clinical success (resolution of signs and symptoms of acute cystitis demonstrated at the TOC visit persist at the FU visit and no new signs and symptoms, without receiving other AB before the FU visit \[or AB for uUTI on day of FU visit\]). Lack of clinical or microbiological success (including missing outcome assessments) was considered as therapeutic failure.

Time frame:
FU visit (Days 21 to 31)
Reported as:
Count of participants · Participants
Number of Participants With Therapeutic Response (TR) (Combined Per Participant Clinical and Microbiological Response) at the Follow up (FU) Visit-Micro-ITT NTF-S Population
ParticipantsGepotidacinNitrofurantoin
Therapeutic Success11794
Therapeutic Failure219204
SecondaryNumber of Participants With Clinical Outcome at the Follow up (FU) Visit - Micro-ITT NTF-S Population

Clinical outcomes at FU were categorized as SCR, DCR, CI, CW, CR and UTD. SCR at FU was resolution of symptoms of acute cystitis demonstrated at the TOC persist at the FU (and no symptoms), without receiving other AB before the FU. DCR at FU was resolution of symptoms of acute cystitis present at BL after clinical failure at TOC without receiving AB before FU. CI at FU was improvement in CSS from BL, but not complete resolution without receiving AB before FU. CW at FU was worsening or no change in CSS at FU compared to BL after clinical failure at TOC or receiving other AB for the current infection (uUTI) before or on the date of the FU. CR at FU was symptoms of acute cystitis reoccur at FU after clinical success at TOC. Unable to determine outcome criteria at FU were BL score missing, FU assessment missing or received other AB not for the current infection (uUTI) prior to the assessment (unless CS or CR outcome criteria were met).

Time frame:
FU visit (Days 21 to 31)
Reported as:
Count of participants · Participants
Number of Participants With Clinical Outcome at the Follow up (FU) Visit - Micro-ITT NTF-S Population
ParticipantsGepotidacinNitrofurantoin
Sustained clinical resolution (SCR)184162
Delayed clinical resolution (DCR)6144
Clinical improvement (CI)2827
Clinical worsening (CW)1223
Clinical recurrence (CR)1111
Unable to determine (UTD)4031
SecondaryNumber of Participants With Clinical Response at the Follow up (FU) Visit - Micro-ITT NTF-S Population

Clinical response at FU was categorized as clinical success and clinical failure. Clinical success at FU was defined as resolution of symptoms of acute cystitis demonstrated at TOC persist at the FU visit (and no new symptoms), without receiving other AB before the FU visit. Lack of sustained clinical resolution or a missing outcome assessment was defined as clinical failure.

Time frame:
FU visit (Days 21 to 31)
Reported as:
Count of participants · Participants
Number of Participants With Clinical Response at the Follow up (FU) Visit - Micro-ITT NTF-S Population
ParticipantsGepotidacinNitrofurantoin
Clinical success184162
Clinical failure152136
SecondaryNumber of Participants With Microbiological Outcome (MO) at the Follow up (FU) Visit - Micro-ITT NTF-S Population

Participant-level MOs at FU were categorized as sustained microbiological eradication (SME), microbiological recurrence (MR), microbiological persistence (MP), delayed microbiological eradication (DME) and unable to determine (UTD). SME at FU was defined as all baseline QUPs had an outcome of sustained eradication at FU (i.e., \<10\^3 CFU/mL without the participant receiving other systemic antimicrobials before the FU Visit). MR at FU was defined as at least one QUP had an outcome of recurrence (≥10\^3 CFU/mL) and none had an outcome of persistence at FU. MP at FU was defined as at least one QUP had an outcome of persistence at FU. DME at FU was defined as at least one QUP had an outcome of delayed eradication and none had an outcome of persistence or recurrence at FU. UTD at FU was defined as all QUP outcomes were unable to determine at FU.

Time frame:
FU visit (Days 21 to 31)
Reported as:
Count of participants · Participants
Number of Participants With Microbiological Outcome (MO) at the Follow up (FU) Visit - Micro-ITT NTF-S Population
ParticipantsGepotidacinNitrofurantoin
Sustained microbiological eradication (SME)174136
Microbiological persistence (MP)3238
Microbiological recurrence (MR)3635
Delayed microbiological eradication (DME)3431
Unable to determine (UTD)6058
SecondaryNumber of Participants With Microbiological Response at the Follow up (FU) Visit - Micro-ITT NTF-S Population

Participant- level microbiological response at FU was categorized as microbiological success and microbiological failure. Microbiological success at FU was defined as all baseline QUPs had a microbiological outcome of sustained eradication at FU visit. Microbiological failure at FU was defined as not meeting criteria of microbiological success including those participants with UTD outcome.

Time frame:
FU visit (Days 21 to 31)
Reported as:
Count of participants · Participants
Number of Participants With Microbiological Response at the Follow up (FU) Visit - Micro-ITT NTF-S Population
ParticipantsGepotidacinNitrofurantoin
Microbiological Success174136
Microbiological Failure162162
SecondaryNumber of Participants With Clinical Outcome at the TOC Visit - Intent-to-Treat (ITT) Population

Clinical outcomes at TOC were categorized as clinical resolution, clinical improvement, clinical worsening and unable to determine. Clinical resolution at TOC was defined as resolution symptoms of acute cystitis present at baseline (BL) (and no symptoms) without receiving any other AB before the TOC visit. Clinical improvement at TOC was defined as improvement (but not complete resolution) in CSS from BL, without receiving any other AB before the TOC visit. Clinical worsening at TOC was defined as worsening or no change in CSS from BL or received other AB for the current infection (uUTI) before or on the date of the TOC visit. Unable to determine outcome criteria were: BL score is missing (and thus improvement/worsening cannot be determined), TOC assessment is missing, or receipt of other AB not for the current infection before the TOC visit (unless clinical worsening outcome criteria were met).

Time frame:
TOC visit (Days 9 to 16)
Reported as:
Count of participants · Participants
Number of Participants With Clinical Outcome at the TOC Visit - Intent-to-Treat (ITT) Population
ParticipantsGepotidacinNitrofurantoin
Clinical resolution497484
Clinical improvement194206
Clinical worsening2637
Unable to determine5037
SecondaryNumber of Participants With Clinical Response at the TOC Visit - Intent-to-Treat (ITT) Population

Clinical response at TOC was categorized as clinical success and clinical failure. Clinical success at TOC was defined as resolution of signs and symptoms of acute cystitis present at BL (and no new symptoms), without receiving any other AB before the TOC visit. Lack of resolution, including receipt of an AB for uUTI at the TOC visit, or a missing outcome assessment was defined as Clinical Failure.

Time frame:
TOC visit (Days 9 to 16)
Reported as:
Count of participants · Participants
Number of Participants With Clinical Response at the TOC Visit - Intent-to-Treat (ITT) Population
ParticipantsGepotidacinNitrofurantoin
Clinical success497484
Clinical failure270280
SecondaryNumber of Participants With Clinical Outcome at the Follow up (FU) Visit - Intent-to-Treat (ITT) Population

Clinical outcomes at FU were categorized as Sustained Clinical Response (SCR), Delayed Clinical Response (DCR), CI, CW, Clinical Recurrence (CR) and UTD. SCR at FU was resolution of symptoms of acute cystitis demonstrated at TOC persist at the FU (and no symptoms), without receiving other AB before the FU. DCR at FU was resolution of symptoms of acute cystitis present at BL after clinical failure at TOC without receiving AB before FU. CI at FU was improvement in CSS from BL, but not complete resolution without receiving AB before FU. CW at FU was worsening or no change in CSS at FU compared to BL after clinical failure at TOC or receiving other AB for the current infection (uUTI) before or on the date of the FU. CR at FU was symptoms of acute cystitis reoccur at FU after clinical success at TOC. UTD outcome criteria at FU were BL score missing, FU assessment missing or received other AB not for current infection (uUTI) prior to assessment (unless CS or CR outcome criteria were met).

Time frame:
FU visit (Days 21 to 31)
Reported as:
Count of participants · Participants
Number of Participants With Clinical Outcome at the Follow up (FU) Visit - Intent-to-Treat (ITT) Population
ParticipantsGepotidacinNitrofurantoin
Sustained clinical resolution (SCR)421404
Delayed clinical resolution (DCR)130127
Clinical improvement (CI)7571
Clinical worsening (CW)2948
Clinical recurrence (CR)2530
Unable to determine (UTD)8784
SecondaryNumber of Participants With Clinical Response at the Follow up (FU) Visit - Intent-to-Treat (ITT) Population

Clinical response at FU was categorized as clinical success and clinical failure. Clinical success at FU was defined as resolution of symptoms of acute cystitis demonstrated at TOC persist at the FU visit (and no new symptoms), without receiving other AB before the FU visit. Lack of sustained clinical resolution or a missing outcome assessment was defined as clinical failure.

Time frame:
FU visit (Days 21 to 31)
Reported as:
Count of participants · Participants
Number of Participants With Clinical Response at the Follow up (FU) Visit - Intent-to-Treat (ITT) Population
ParticipantsGepotidacinNitrofurantoin
Clinical success421404
Clinical failure346360
SecondaryPlasma Concentration of Gepotidacin

Blood samples were collected for plasma concentration of gepotidacin.

Time frame:
Baseline (Day 1) 0-2 hour (h) and >2h post-dose; On-therapy (Day 2), morning (am) pre-dose, 0-6h, 6-8h, 8-10h, 10-12h post-dose, 0-2h, >2h evening (pm) post-dose; On-therapy (Day 3 to 5), 0-6h, 6-8h, 8-10h, 10-12h post-dose
Reported as:
Mean · Microgram/millilitre (ug/mL)
Plasma Concentration of Gepotidacin
Microgram/millilitre (ug/mL)Gepotidacin
Baseline Day 1, 0-2hour (h) post-dose8.52 ± 84.21
Baseline Day 1, >2h post-dose2.96 ± 1.865
On-Therapy Day 2, am, pre-dose3.48 ± 21.58
On-Therapy Day 2, 0-6h, am, post-dose4.20 ± 4.210
On-Therapy Day 2, 6-8h, am, post-dose1.22 ± 0.4729
On-Therapy Day 2, 8-10h, am, post-dose1.10 ± 1.103
On-Therapy Day 2, 10-12h, am, post-dose1.26 ± 1.358
On-Therapy Day 2, 0-2h, pm post-dose2.56 ± 2.717
On-Therapy Day 2, >2h, pm, post-dose2.61 ± 2.579
On-Therapy Day 3 to 5, 0-6h post-dose4.10 ± 3.955
On-Therapy Day 3 to 5, 6-8h post-dose2.54 ± 3.006
On-Therapy Day 3 to 5, 8-10h post-dose1.08 ± 0.9247
On-Therapy Day 3 to 5, 10-12h post-dose1.17 ± 1.688
SecondaryUrine Concentration of Gepotidacin

Urine samples were collected from participants.

Time frame:
Baseline (Day 1) 0-2 hour (h) and >2h post-dose; On-therapy (Day 2), morning (am) pre-dose, 0-6h, 6-8h, 8-10h, 10-12h post-dose, 0-2h, >2h evening (pm) post-dose; On-therapy (Day 3 to 5), 0-6h, 6-8h, 8-10h, 10-12h post-dose
Reported as:
Mean · ug/mL
Urine Concentration of Gepotidacin
ug/mLGepotidacin
Baseline Day 1, 0-2hour (h) post-dose317 ± 680.3
Baseline Day 1, >2h post-dose857 ± 1539
On-Therapy Day 2, am, pre-dose391 ± 402.5
On-Therapy Day 2, 0-6h, am, post-dose781 ± 1449
On-Therapy Day 2, 6-8h, am, post-dose363 ± 443.7
On-Therapy Day 2, 8-10h, am, post-dose326 ± 274.4
On-Therapy Day 2, 10-12h, am, post-dose287 ± 423.2
On-Therapy Day 2, 0-2h, pm post-dose156 ± 216.1
On-Therapy Day 2, >2h, pm, post-dose624
On-Therapy Day 3 to 5, 0-6h post-dose651 ± 1313
On-Therapy Day 3 to 5, 6-8h post-dose259 ± 164.9
On-Therapy Day 3 to 5, 8-10h post-dose522 ± 663.1
On-Therapy Day 3 to 5, 10-12h post-dose370 ± 498.8
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment.

Time frame:
From the time of first dose (Day 1) through the final follow-up visit (Day 21-31)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsGepotidacinNitrofurantoin
Number of Participants With Treatment-emergent Adverse Events (TEAEs)266165
SecondaryNumber of Participants With Serious Adverse Events (SAEs)

An SAE is defined as any untoward medical occurrence that, at any dose may result in death or is life-threatening or requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity or is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment or is associated with liver injury and impaired liver function.

Time frame:
From the time of first dose (Day 1) through the final follow-up visit (Day 21-31)
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs)
ParticipantsGepotidacinNitrofurantoin
Number of Participants With Serious Adverse Events (SAEs)23
SecondaryChange From Baseline in Hematology Parameters - Neutrophil Count, Lymphocyte Count, Monocyte Count, Eosinophil Count, Basophil Count and Platelet Count at On Therapy and Test of Cure Visit

Blood samples were collected for the analysis of hematology parameters: neutrophil count, lymphocyte count, monocyte count, eosinophil count, basophil count and platelet count. Baseline is defined as the latest pre-dose assessment with a non-missing value.

Time frame:
Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)
Reported as:
Mean · Giga cells per Liter (10^9 cells/L)
Change From Baseline in Hematology Parameters - Neutrophil Count, Lymphocyte Count, Monocyte Count, Eosinophil Count, Basophil Count and Platelet Count at On Therapy and Test of Cure Visit
Giga cells per Liter (10^9 cells/L)GepotidacinNitrofurantoin
Basophils, Baseline0.053 ± 0.2170.055 ± 0.0256
Basophils, On-Therapy-0.001 ± 0.1870.000 ± 0.0204
Basophils, Test of Cure0.002 ± 0.02040.001 ± 0.0244
Eosinophils, Baseline0.152 ± 0.11370.154 ± 0.1338
Eosinophils, On-Therapy0.013 ± 0.06800.017 ± 0.0691
Eosinophils, Test of Cure0.024 ± 0.07700.022 ± 0.0865
Lymphocytes, Baseline2.074 ± 0.66032.133 ± 2.0797
Lymphocytes, On-Therapy0.009 ± 0.4233-0.026 ± 0.5333
Lymphocytes, Test of Cure-0.003 ± 0.51060.067 ± 0.6268
Monocytes, Baseline0.528 ± 0.18080.529 ± 0.1906
Monocytes, On-Therapy-0.022 ± 0.1445-0.018 ± 0.1400
Monocytes, Test of Cure-0.022 ± 0.1528-0.010 ± 0.1678
Neutrophils, Baseline4.715 ± 1.97814.640 ± 1.8018
Neutrophils, On-Therapy-0.540 ± 1.5771-0.519 ± 1.4975
Neutrophils, Test of Cure-0.703 ± 1.7653-0.470 ± 1.7541
Platelets, Baseline278.0 ± 70.32279.0 ± 73.76
Platelets, On-Therapy2.4 ± 24.462.6 ± 29.94
Platelets, Test of Cure3.0 ± 39.748.6 ± 47.92
SecondaryChange From Baseline in Hematology Parameter-hemoglobin Level at On Therapy and Test of Cure Visit

Blood samples were collected for the analysis of hemoglobin level. Baseline is defined as the latest pre-dose assessment with a non-missing value.

Time frame:
Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)
Reported as:
Mean · Gram per Liter (g/L)
Change From Baseline in Hematology Parameter-hemoglobin Level at On Therapy and Test of Cure Visit
Gram per Liter (g/L)GepotidacinNitrofurantoin
Hemoglobin, Baseline132.2 ± 13.13131.7 ± 14.33
Hemoglobin, On-Therapy-0.1 ± 5.27-0.4 ± 6.39
Hemoglobin, Test of Cure-0.9 ± 6.63-1.6 ± 7.27
SecondaryChange From Baseline in Hematology Parameter- Hematocrit Level at On Therapy and Test of Cure Visit

Blood samples were collected for the analysis of hematocrit level. Baseline is defined as the latest pre-dose assessment with a non-missing value.

Time frame:
Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)
Reported as:
Mean · Percentage of hematocrit
Change From Baseline in Hematology Parameter- Hematocrit Level at On Therapy and Test of Cure Visit
Percentage of hematocritGepotidacinNitrofurantoin
Hematocrit, Baseline0.4302 ± 0.042920.4282 ± 0.4584
Hematocrit, On-Therapy0.0003 ± 0.02238-0.0007 ± 0.02431
Hematocrit, Test of Cure-0.0023 ± 0.02689-0.0055 ± 0.02757
SecondaryChange From Baseline in Hematology Parameter- Erythrocytes Count at On Therapy and Test of Cure Visit

Blood samples were collected for the analysis of erythrocytes count. Baseline is defined as the latest pre-dose assessment with a non-missing value.

Time frame:
Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)
Reported as:
Mean · Tera cells per Liter (10^12 cells/L)
Change From Baseline in Hematology Parameter- Erythrocytes Count at On Therapy and Test of Cure Visit
Tera cells per Liter (10^12 cells/L)GepotidacinNitrofurantoin
Erythrocytes, Baseline4.538 ± 0.43154.515 ± 0.4324
Erythrocytes, On-Therapy-0.005 ± 0.1900-0.011 ± 0.2247
Erythrocytes, Test of Cure-0.033 ± 0.2377-0.048 ± 0.2528
SecondaryChange From Baseline in Hematology Parameter - Mean Corpuscular Hemoglobin (MCH) at On Therapy and Test of Cure Visit

Blood samples were collected for the analysis of MCH. Baseline is defined as the latest pre-dose assessment with a non-missing value.

Time frame:
Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)
Reported as:
Mean · Picogram (pg)
Change From Baseline in Hematology Parameter - Mean Corpuscular Hemoglobin (MCH) at On Therapy and Test of Cure Visit
Picogram (pg)GepotidacinNitrofurantoin
MCH, Baseline29.20 ± 2.39229.24 ± 2.499
MCH, On-Therapy0.02 ± 0.500-0.03 ± 0.536
MCH, Test of Cure0.02 ± 0.596-0.05 ± 0.644
SecondaryChange From Baseline in Hematology Parameter - Mean Corpuscular Volume (MCV) at On Therapy and Test of Cure Visit

Blood samples were collected for the analysis of MCV. Baseline is defined as the latest pre-dose assessment with a non-missing value.

Time frame:
Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)
Reported as:
Mean · Femtoliter (fL)
Change From Baseline in Hematology Parameter - Mean Corpuscular Volume (MCV) at On Therapy and Test of Cure Visit
Femtoliter (fL)GepotidacinNitrofurantoin
MCV, Baseline95.02 ± 7.05795.03 ± 7.438
MCV, On-Therapy0.17 ± 3.2690.07 ± 3.248
MCV, Test of Cure0.17 ± 3.511-0.019 ± 3.689
SecondaryChange From Baseline in Clinical Chemistry Parameters - Serum Urea Nitrogen, Glucose, Calcium, Chloride, Sodium, Magnesium, Phosphate, and Potassium Levels at On Therapy and Test of Cure Visit

Blood samples were collected for the analysis of clinical chemistry parameters. Baseline is defined as the latest pre-dose assessment with a non-missing value

Time frame:
Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)
Reported as:
Mean · millimoles per liter (mmol/L)
Change From Baseline in Clinical Chemistry Parameters - Serum Urea Nitrogen, Glucose, Calcium, Chloride, Sodium, Magnesium, Phosphate, and Potassium Levels at On Therapy and Test of Cure Visit
millimoles per liter (mmol/L)GepotidacinNitrofurantoin
Serum Calcium, Baseline2.357 ± 0.11182.374 ± 0.1154
Serum Calcium, On-Therapy-0.009 ± 0.0914-0.012 ± 0.992
Serum Calcium, Test of Cure-0.016 ± 0.0981-0.016 ± 0.1017
Serum Chloride, Baseline101.6 ± 3.23101.3 ± 3.08
Serum Chloride, On-Therapy0.2 ± 2.590.0 ± 2.49
Serum Chloride, Test of Cure0.4 ± 2.880.2 ± 2.67
Serum Glucose, Baseline5.778 ± 2.36655.689 ± 1.9348
Serum Glucose, On-Therapy0.199 ± 1.47280.397 ± 1.5986
Serum Glucose, Test of Cure0.156 ± 1.58930.290 ± 1.5996
Serum Magnesium, Baseline0.836 ± 0.07600.831 ± 0.0781
Serum Magnesium, On-Therapy-0.006 ± 0.0634-0.015 ± 0.0604
Serum Magnesium, Test of Cure-0.008 ± 0.0626-0.014 ± 0.0616
Serum Phosphate, Baseline1.138 ± 0.16411.133 ± 0.1750
Serum Phosphate, On-Therapy0.005 ± 0.1642-0.012 ± 0.1826
Serum Phosphate, Test of Cure0.009 ± 0.18570.008 ± 0.1908
Serum Potassium, Baseline4.32 ± 0.4414.33 ± 0.447
Serum Potassium, On-Therapy0.00 ± 0.443-0.01 ± 0.495
Serum Potassium, Test of Cure0.00 ± 0.4880.01 ± 0.495
Serum Sodium, Baseline139.5 ± 2.69139.2 ± 2.64
Serum Sodium, On-Therapy-0.1 ± 2.41-0.2 ± 2.54
Serum Sodium, Test of Cure0.0 ± 2.68-0.1 ± 2.64
Serum Urea Nitrogen, Baseline4.855 ± 1.88774.912 ± 2.1175
Serum Urea Nitrogen, On-Therapy-0.039 ± 1.1285-0.045 ± 1.1848
Serum Urea Nitrogen, Test of Cure0.031 ± 1.36130.054 ± 1.5544
SecondaryChange From Baseline in Clinical Chemistry Parameters - Total Bilirubin, Direct Bilirubin and Creatinine Levels at On Therapy and Test of Cure Visit

Blood samples were collected for the analysis of clinical chemistry parameters. Baseline is defined as the latest pre-dose assessment with a non-missing value.

Time frame:
Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)
Reported as:
Mean · micromoles per Liter (umol/L)
Change From Baseline in Clinical Chemistry Parameters - Total Bilirubin, Direct Bilirubin and Creatinine Levels at On Therapy and Test of Cure Visit
micromoles per Liter (umol/L)GepotidacinNitrofurantoin
Serum direct bilirubin, Baseline4.71 ± 1.5344.78 ± 1.462
Serum direct bilirubin, On-Therapy-0.26 ± 1.443-0.16 ± 1.276
Serum direct bilirubin, Test of cure-0.24 ± 1.577-0.08 ± 1.534
Serum Creatinine, Baseline59.5 ± 20.6759.3 ± 20.17
Serum Creatinine, On-Therapy2.8 ± 13.512.3 ± 23.79
Serum Creatinine, Test of Cure0.9 ± 16.982.2 ± 29.46
Serum total bilirubin, Baseline6.72 ± 3.9146.77 ± 3.909
Serum total bilirubin, On-Therapy-0.10 ± 2.718-0.15 ± 2.655
Serum total bilirubin, Test of Cure-0.15 ± 2.904-0.16 ± 3.107
SecondaryChange From Baseline in Clinical Chemistry Parameters - Albumin and Protein Levels at On Therapy and Test of Cure Visit

Blood samples were collected for the analysis of clinical chemistry parameters. Baseline is defined as the latest pre-dose assessment with a non-missing value.

Time frame:
Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)
Reported as:
Mean · gram per Liter (g/L)
Change From Baseline in Clinical Chemistry Parameters - Albumin and Protein Levels at On Therapy and Test of Cure Visit
gram per Liter (g/L)GepotidacinNitrofurantoin
Serum Albumin, Baseline45.2 ± 3.0745.4 ± 2.91
Serum Albumin, On-Therapy0.0 ± 2.21-0.3 ± 2.06
Serum Albumin, Test of Cure-0.5 ± 2.42-0.5 ± 2.50
Serum Protein, Baseline71.6 ± 4.7371.8 ± 4.72
Serum Protein, On-Therapy0.0 ± 3.70-0.4 ± 3.46
Serum Protein, Test of Cure-0.9 ± 4.02-1.0 ± 3.76
SecondaryChange From Baseline in Clinical Chemistry Parameters - Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) and Alkaline Phosphatase (ALP) Levels at On Therapy and Test of Cure Visit

Blood samples were collected for the analysis of clinical chemistry parameters. Baseline is defined as the latest pre-dose assessment with a non-missing value.

Time frame:
Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)
Reported as:
Mean · Units per Liter (U/L)
Change From Baseline in Clinical Chemistry Parameters - Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) and Alkaline Phosphatase (ALP) Levels at On Therapy and Test of Cure Visit
Units per Liter (U/L)GepotidacinNitrofurantoin
Serum ALP, Baseline79.0 ± 27.9878.4 ± 30.89
Serum ALP, On-Therapy-0.5 ± 6.910.1 ± 7.24
Serum ALP, Test of Cure-1.5 ± 9.430.0 ± 12.65
Serum AST, Baseline20.1 ± 9.4021.5 ± 16.55
Serum AST, On-Therapy0.5 ± 5.970.1 ± 5.33
Serum AST, Test of Cure1.1 ± 7.211.6 ± 38.77
Serum ALT, Baseline18.9 ± 13.5520.0 ± 17.84
Serum ALT, On-Therapy0.8 ± 5.170.2 ± 5.43
Serum ALT, Test of Cure1.0 ± 8.931.2 ± 23.91
SecondaryNumber of Participants With Urinalysis Dipstick Results at Baseline, On Therapy and Test of Cure Visit

Urine samples were collected for urinalysis: Urine Glucose (GLU), Urine Protein (PRO), Urine Occult Blood (BLO), Urine Ketones (KET), Urine Nitrite (NIT) and Urine Leukocyte Esterase (LEU). Baseline is defined as the latest pre-dose assessment with a non-missing value. The dipstick test gives results in a semi-quantitative manner, and results can be read as Negative, Trace, Small, Moderate, Large, Positive, 50 mg/dL, 150 mg/dL, \>=500 mg/dL, 30 mg/dL, 100 mg/dL, 200 mg/dL, 5 mg/dL, 20 mg/dL and 80 mg/dL indicating concentrations in the urine sample. In the row title (GLU, Baseline, Negative), GLU indicates parameter, Baseline is the visit and Negative indicates the concentration in the urine sample. Data is presented in similar manner for all other parameters.

Time frame:
Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)
Reported as:
Count of participants · Participants
Number of Participants With Urinalysis Dipstick Results at Baseline, On Therapy and Test of Cure Visit
ParticipantsGepotidacinNitrofurantoin
GLU, Baseline, Negative703717
GLU, Baseline, 50 mg/dL155
GLU, Baseline, 150 mg/dL43
GLU, Baseline, >= 500 mg/dL2115
GLU, On-Therapy, Negative681680
GLU, On-Therapy, 50 mg/dL116
GLU, On-Therapy, 150 mg/dL74
GLU, On-Therapy, >= 500 mg/dL2221
GLU, Test of Cure, Negative672672
GLU, Test of Cure, 50 mg/dL64
GLU, Test of Cure, 150 mg/dL24
GLU, Test of Cure, >= 500 mg/dL2120
PRO, Baseline, Negative501501
PRO, Baseline, 30 mg/dL179160
PRO, Baseline, 100 mg/dL6072
PRO, Baseline, >=500 mg/dL36
PRO, On-Therapy, Negative546587
PRO, On-Therapy, 30 mg/dL133102
PRO, On-Therapy, 100 mg/dL4020
PRO, On-Therapy, >=500 mg/dL22
PRO, Test of Cure, Negative602591
PRO, Test of Cure, 30 mg/dL7789
PRO, Test of Cure, 100 mg/dL2115
PRO, Test of Cure, >=500 mg/dL15
BLO, Baseline, Negative310297
BLO, Baseline, Positive20
BLO, Baseline, Small248266
BLO, Baseline, Moderate118107
BLO, Baseline, Large7275
BLO, On-Therapy, Negative531475
BLO, On-Therapy, Small123167
BLO, On-Therapy, Moderate3840
BLO, On-Therapy, Large2929
BLO, Test of Cure, Negative503510
BLO, Test of Cure, Small124114
BLO, Test of Cure, Moderate4650
BLO, Test of Cure, Large2826
KET, Baseline, Negative724726
KET, Baseline, 5 mg/dL148
KET, Baseline, 20 mg/dL45
KET, Baseline, >=80 mg/dL11
KET, On-Therapy, Negative704688
KET, On-Therapy, 5 mg/dL1020
KET, On-Therapy, 20 mg/dL62
KET, On-Therapy, >=80 mg/dL11
KET, Test of Cure, Negative683688
KET, Test of Cure, 5 mg/dL1311
KET, Test of Cure, >=80 mg/dL51
NIT, Baseline, Negative466458
NIT, Baseline, Positive286291
NIT, On-Therapy, Negative655647
NIT, On-Therapy, Positive6664
NIT, Test of Cure, Negative662639
NIT, Test of Cure, Positive3961
LEU, Baseline, Negative186169
LEU, Baseline, Trace8077
LEU, Baseline, Small8974
LEU, Baseline, Moderate109116
LEU, Baseline, Large292314
LEU, Baseline, Positive02
LEU, On-Therapy, Negative429387
LEU, On-Therapy, Trace8286
LEU, On-Therapy, Small4869
LEU, On-Therapy, Moderate5763
LEU, On-Therapy, Large105106
LEU, Test of Cure, Negative506442
LEU, Test of Cure, Trace6073
LEU, Test of Cure, Small3854
LEU, Test of Cure, Moderate3850
LEU, Test of Cure, Large5981
SecondaryAbsolute Mean Values of Urine Specific Gravity at Baseline, On Therapy and Test of Cure Visit

Urine samples were collected from participants to assess urine specific gravity. Baseline is defined as the latest pre-dose assessment with a non-missing value.

Time frame:
Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)
Reported as:
Mean · Ratio
Absolute Mean Values of Urine Specific Gravity at Baseline, On Therapy and Test of Cure Visit
RatioGepotidacinNitrofurantoin
Urine Specific Gravity, Baseline1.0168 ± 0.006391.0166 ± 0.00636
Urine Specific Gravity, On-Therapy1.0175 ± 0.006631.0166 ± 0.00636
Urine Specific Gravity, Test of Cure1.0179 ± 0.007001.0179 ± 0.00701
SecondaryAbsolute Mean Values of Urine Potential of Hydrogen (pH) at Baseline, On Therapy and Test of Cure Visit

Urine samples were collected from participants to assess urine pH levels. Baseline is defined as the latest pre-dose assessment with a non-missing value.

Time frame:
Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)
Reported as:
Mean · pH
Absolute Mean Values of Urine Potential of Hydrogen (pH) at Baseline, On Therapy and Test of Cure Visit
pHGepotidacinNitrofurantoin
Urine pH, Baseline5.6 ± 0.765.7 ± 0.79
Urine pH, On-Therapy5.6 ± 0.685.6 ± 0.73
Urine pH, Test of Cure5.6 ± 0.685.6 ± 0.70
SecondaryChange From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at On-Therapy and Test of Cure Visit

SBP and DBP were measured in a semi-supine position after 5 minutes rest. Baseline is defined as the latest pre-dose assessment with a non-missing value.

Time frame:
Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)
Reported as:
Mean · Millimeters of mercury (mmHg)
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at On-Therapy and Test of Cure Visit
Millimeters of mercury (mmHg)GepotidacinNitrofurantoin
SBP, Baseline123.1 ± 13.23123.4 ± 12.61
SBP, On-Therapy-0.8 ± 9.20-1.4 ± 9.64
SBP, Test of Cure-0.9 ± 10.44-1.2 ± 10.86
DBP, Baseline76.5 ± 8.3676.7 ± 8.25
DBP, On-Therapy-0.2 ± 7.48-0.7 ± 7.33
DBP, Test of Cure-0.5 ± 7.80-1.2 ± 8.28
SecondaryChange From Baseline in Pulse Rate at On Therapy and Test of Cure Visit

Pulse rate was measured in a semi-supine position after 5 minutes rest. Baseline is defined as the latest pre-dose assessment with a non-missing value.

Time frame:
Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)
Reported as:
Mean · beats per minute (bpm)
Change From Baseline in Pulse Rate at On Therapy and Test of Cure Visit
beats per minute (bpm)GepotidacinNitrofurantoin
Pulse rate, Baseline73.5 ± 9.8473.3 ± 9.91
Pulse rate, On-Therapy1.4 ± 8.391.7 ± 8.80
Pulse rate, Test of Cure1.2 ± 9.631.0 ± 10.18
SecondaryChange From Baseline in Body Temperature at On Therapy and Test of Cure Visit

Temperature was measured in a semi-supine position after 5 minutes rest. Baseline is defined as the latest pre-dose assessment with a non-missing value.

Time frame:
Baseline (on or before Day 1), On-Therapy (Days 2 to 5), and Test of cure (Days 9 to 16)
Reported as:
Mean · celsius
Change From Baseline in Body Temperature at On Therapy and Test of Cure Visit
celsiusGepotidacinNitrofurantoin
Temperature, Baseline36.62 ± 0.37236.62 ± 0.406
Temperature, On-Therapy-0.04 ± 0.300-0.04 ± 0.379
Temperature, Test of Cure-0.04 ± 0.330-0.07 ± 0.400

Adverse events

Collected over All cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected from the time of first dose (Day 1) through the final follow-up visit (Day 21-31).. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Gepotidacin0/766 (0%)2/766 (0.3%)207/766 (27%)
Nitrofurantoin0/760 (0%)3/760 (0.4%)94/760 (12.4%)
Most frequent serious events
Most frequent serious events
EventGepotidacinNitrofurantoin
LymphadenopathyBlood and lymphatic system disorders0/7661/760
Dengue feverInfections and infestations0/7661/760
Food intoleranceMetabolism and nutrition disorders0/7661/760
Lumbar radiculopathyNervous system disorders0/7661/760
SciaticaNervous system disorders0/7661/760
Enterovesical fistulaGastrointestinal disorders1/7660/760
DysarthriaNervous system disorders1/7660/760
Most frequent other events
Most frequent other events
EventGepotidacinNitrofurantoin
DiarrhoeaGastrointestinal disorders111/76627/760
NauseaGastrointestinal disorders81/76629/760
Abdominal pain upperGastrointestinal disorders20/7668/760
HeadacheNervous system disorders17/76618/760
FlatulenceGastrointestinal disorders15/7664/760
Faeces softGastrointestinal disorders14/7664/760
DizzinessNervous system disorders11/7668/760
VomitingGastrointestinal disorders10/7663/760
Urinary tract infectionInfections and infestations8/7665/760
Aspartate aminotransferase increasedInvestigations8/7665/760

Baseline characteristics

Participants randomly assigned to the study treatment were included in the ITT population.

Age, Customized
Age, Customized(Years)GepotidacinNitrofurantoinTotal
Mean49.6 ± 17.8250.4 ± 18.1750.0 ± 17.99
Age, Customized
Age, Customized(Participants)GepotidacinNitrofurantoinTotal
Less than (<) 18 years6915
More than or equal to (>=) 18 years to 50 years372369741
More than (>) 50 years389386775
Sex/Gender, Customized
Sex/Gender, Customized(Participants)GepotidacinNitrofurantoinTotal
Female7677641531
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)GepotidacinNitrofurantoinTotal
Hispanic or Latino278270548
Not Hispanic or Latino489494983
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)GepotidacinNitrofurantoinTotal
American Indian or Alaska Native6275137
Asian232144
Native Hawaiian or Other Pacific Islander314
Black or African American404080
White6276211248
More than one race12618
Unknown or Not Reported000
Baseline Acute Cystitis Recurrence
Baseline Acute Cystitis Recurrence(Participants)GepotidacinNitrofurantoinTotal
Recurrent Infection312309621
Non-Recurrent Infection455455910
08

Study locations

104 sites
  • GSK Investigational Site
    Birmingham, Alabama 35205, United States
  • GSK Investigational Site
    Phoenix, Arizona 85051, United States
  • GSK Investigational Site
    Tucson, Arizona 85712, United States
  • GSK Investigational Site
    Beverly Hills, California 90211-2921, United States
  • GSK Investigational Site
    Chula Vista, California 91911, United States
  • GSK Investigational Site
    La Mesa, California 91942, United States
  • GSK Investigational Site
    Lomita, California 90717, United States
  • GSK Investigational Site
    Long Beach, California 90806, United States
  • GSK Investigational Site
    Northridge, California 91324-3331, United States
  • GSK Investigational Site
    Northridge, California 91324-3528, United States
  • GSK Investigational Site
    Palm Springs, California 92264, United States
  • GSK Investigational Site
    San Diego, California 92120, United States
  • GSK Investigational Site
    DeLand, Florida 32720, United States
  • GSK Investigational Site
    Hialeah, Florida 33016, United States
  • GSK Investigational Site
    Miami Springs, Florida 33166, United States
  • GSK Investigational Site
    Miami, Florida 33144, United States
  • GSK Investigational Site
    Orlando, Florida 32806, United States
  • GSK Investigational Site
    Pompano Beach, Florida 33060, United States
  • GSK Investigational Site
    Atlanta, Georgia 30328, United States
  • GSK Investigational Site
    Columbus, Georgia 31901-2561, United States
  • GSK Investigational Site
    Fayetteville, Georgia 31204, United States
  • GSK Investigational Site
    Wichita, Kansas 67226-3007, United States
  • GSK Investigational Site
    New Orleans, Louisiana 70115, United States
  • GSK Investigational Site
    Shreveport, Louisiana 71106, United States
  • GSK Investigational Site
    Watertown, Massachusetts 02472, United States
  • GSK Investigational Site
    Dearborn Heights, Michigan 48127-3163, United States
  • GSK Investigational Site
    Norfolk, Nebraska 68701-2669, United States
  • GSK Investigational Site
    East Brunswick, New Jersey 08816-1407, United States
  • GSK Investigational Site
    Albuquerque, New Mexico 87109, United States
  • GSK Investigational Site
    Endwell, New York 13760, United States
  • GSK Investigational Site
    Fayetteville, North Carolina 28304, United States
  • GSK Investigational Site
    Scottdale, Pennsylvania 15683, United States
  • GSK Investigational Site
    Smithfield, Pennsylvania 15478, United States
  • GSK Investigational Site
    Clarksville, Tennessee 37043-1524, United States
  • GSK Investigational Site
    Memphis, Tennessee 38120, United States
  • GSK Investigational Site
    Arlington, Texas 76014, United States
  • GSK Investigational Site
    Austin, Texas 78705, United States
  • GSK Investigational Site
    Corpus Christi, Texas 78414, United States
  • GSK Investigational Site
    Forney, Texas 75126, United States
  • GSK Investigational Site
    Houston, Texas 77055, United States
  • GSK Investigational Site
    Houston, Texas 77065-5597, United States
  • GSK Investigational Site
    Blagoevgrad, 2700, Bulgaria
  • GSK Investigational Site
    Dupnitsa, 2600, Bulgaria
  • GSK Investigational Site
    Pernik, 5800, Bulgaria
  • GSK Investigational Site
    Pleven, 5800, Bulgaria
  • GSK Investigational Site
    Plovdiv, 4000, Bulgaria
  • GSK Investigational Site
    Sliven, 8800, Bulgaria
  • GSK Investigational Site
    Smolyan, 4700, Bulgaria
  • GSK Investigational Site
    Sofia, 1000, Bulgaria
  • GSK Investigational Site
    Sofia, 1408, Bulgaria
  • GSK Investigational Site
    Sofia, 1431, Bulgaria
  • GSK Investigational Site
    Yambol, 8600, Bulgaria
  • GSK Investigational Site
    Bory, 305 99, Czechia
  • GSK Investigational Site
    Kromeríž, 767 01, Czechia
  • GSK Investigational Site
    Praha, 120 00, Czechia
  • GSK Investigational Site
    Giessen, Hessen 35385, Germany
  • GSK Investigational Site
    Essen, Nordrhein-Westfalen 45355, Germany
  • GSK Investigational Site
    Muelheim an der Ruhr, Nordrhein-Westfalen 45468, Germany
  • GSK Investigational Site
    Berlin, 10439, Germany
  • GSK Investigational Site
    Hamburg, 20146, Germany
  • GSK Investigational Site
    Heraklion, 71110, Greece
  • GSK Investigational Site
    Larisa, 41110, Greece
  • GSK Investigational Site
    Thessaloniki, 546 42, Greece
  • GSK Investigational Site
    Thessaloniki, 54635, Greece
  • GSK Investigational Site
    Thessaloniki, 56403, Greece
  • GSK Investigational Site
    Ballószög, 6035, Hungary
  • GSK Investigational Site
    Csongrad, 6640, Hungary
  • GSK Investigational Site
    Nyíregyháza, 4400, Hungary
  • GSK Investigational Site
    Orosháza-Szentetornya, 5905, Hungary
  • GSK Investigational Site
    Ahmedabad, 380016, India
  • GSK Investigational Site
    Surat, 395002, India
  • GSK Investigational Site
    Varanasi, 221010, India
  • GSK Investigational Site
    Ciudad de Mexico, Campeche 06100, Mexico
  • GSK Investigational Site
    Guadalajara, Jalisco 44160, Mexico
  • GSK Investigational Site
    Guadalajara, Jalisco 44280, Mexico
  • GSK Investigational Site
    Monterrey, Nuevo León 64000, Mexico
  • GSK Investigational Site
    Monterrey, Nuevo León 64460, Mexico
  • GSK Investigational Site
    San Juan del Río, Querétaro 76800, Mexico
  • GSK Investigational Site
    Jalisco, 44130, Mexico
  • GSK Investigational Site
    Bucharest, 021105, Romania
  • GSK Investigational Site
    Bucharest, 022328, Romania
  • GSK Investigational Site
    Bucharest, 050653, Romania
  • GSK Investigational Site
    Bucuresti, 022328, Romania
  • GSK Investigational Site
    Iasi, 700116, Romania
  • GSK Investigational Site
    Oradea, 410469, Romania
  • GSK Investigational Site
    Timisoara, 300736, Romania
  • GSK Investigational Site
    Bratislava, 851 05, Slovakia
  • GSK Investigational Site
    Kosice, 040 01, Slovakia
  • GSK Investigational Site
    Nitra, 949 01, Slovakia
  • GSK Investigational Site
    Pruske, 018 52, Slovakia
  • GSK Investigational Site
    Sala, 927 01, Slovakia
  • GSK Investigational Site
    Trencin, 911 01, Slovakia
  • GSK Investigational Site
    Trencin, 911 05, Slovakia
  • GSK Investigational Site
    Alicante, 03010, Spain
  • GSK Investigational Site
    Cordoba, 140044, Spain
  • GSK Investigational Site
    Madrid, 28023, Spain
  • GSK Investigational Site
    Madrid, 28041, Spain
  • GSK Investigational Site
    Madrid, 28044, Spain
  • GSK Investigational Site
    Madrid, 28050, Spain
  • GSK Investigational Site
    Valencia, 46026, Spain

Showing the first 100 of 104 sites across 12 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Perry C, Hossain M, Powell M, Raychaudhuri A, Scangarella-Oman N, Tiffany C, Xu S, Dumont E, Janmohamed S. Design of Two Phase III, Randomized, Multicenter Studies Comparing Gepotidacin with Nitrofurantoin for the Treatment of Uncomplicated Urinary Tract Infection in Female Participants. Infect Dis Ther. 2022 Dec;11(6):2297-2310. doi: 10.1007/s40121-022-00706-9. Epub 2022 Oct 21. PubMed 36271314 ↗
  • Fishman C, Caverly Rae JM, Posobiec LM, Laffan SB, Lerman SA, Pearson N, Janmohamed S, Dumont E, Nunn-Floyd D, Stanislaus DJ. Novel Bacterial Topoisomerase Inhibitor Gepotidacin Demonstrates Absence of Fluoroquinolone-Like Arthropathy in Juvenile Rats. Antimicrob Agents Chemother. 2022 Nov 15;66(11):e0048322. doi: 10.1128/aac.00483-22. Epub 2022 Oct 18. PubMed 36255258 ↗
  • Scangarella-Oman NE, Hossain M, Hoover JL, Perry CR, Tiffany C, Barth A, Dumont EF. Dose Selection for Phase III Clinical Evaluation of Gepotidacin (GSK2140944) in the Treatment of Uncomplicated Urinary Tract Infections. Antimicrob Agents Chemother. 2022 Mar 15;66(3):e0149221. doi: 10.1128/AAC.01492-21. Epub 2022 Jan 3. PubMed 34978887 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2019 to primary completion in Nov 2022, 37 months.

Results were first posted in Jun 2023, 6 months after primary completion.

Of 23 industry-sponsored phase 3 interventional studies under Urinary Tract Infections, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 37 months is above that.

Counting every sponsor, half of 37 studies reached it within 20 months; a quarter within 14 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2019
First posted
Jul 16, 2019
StartActual
Oct 17, 2019
Primary completionActual
Nov 30, 2022
CompletionActual
Nov 30, 2022
Results first posted
Jun 22, 2023
Last update
Jun 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04020341
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 16, 2019
Start date
Oct 17, 2019
Primary completion
Nov 30, 2022
Completion
Nov 30, 2022
Results posted
Jun 22, 2023
Last update
Jun 22, 2023

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gepotidacin

Start the discussion